BRAIN Biotech AG

  • WKN: 520394
  • ISIN: DE0005203947
  • Land: Deutschland

Nachricht vom 08.06.2021 | 11:00

BRAIN Biotech AG: BRAIN actively supports the UN Global Compact

DGAP-News: BRAIN Biotech AG / Key word(s): Sustainability
08.06.2021 / 11:00
The issuer is solely responsible for the content of this announcement.

Zwingenberg, Germany, June 8, 2021

BRAIN actively supports the UN Global Compact

BRAIN Biotech AG, Germany, now actively supports the UN Global Compact, a voluntary initiative based on company commitments to implement universal sustainability principles and to advance United Nations goals such as the Sustainable Development Goals (SDGs). With our current products and solutions, we already directly address at least five UN sustainability goals.

BRAIN Biotech AG (BRAIN, ISIN DE0005203947 / WKN 520394) now atively supports the UN Global Compact with its corporate responsibility initiative and principles. By joining the UN Global Compact, BRAIN now formally commits to the values of the world's largest initiative for corporate social responsibility and thus commits to ten universal principles concerning human rights, labour standards, environment and climate as well as the prevention of corruption.

With the current products and solutions, BRAIN already directly addresses at least five of the UN Sustainable Development Goals (SDG):

  • SDG 2, Zero Hunger: natural compounds for food preservation
  • SDG 3, Good Health & Well-Being: natural sugar replacement, salt replacement and salt taste enhancers, natural aromas, bioactive plant cosmetic and chronical wound treatment
  • SDG 6, Clean Water & Sanitation: green mining solutions to replace chemical hazards
  • SDG 9, Industry, Innovation & Infrastructure: biotechnological production, improving production efficiencies for resource conservation, fermented food from side-streams, microbial CO2 usage
  • SDG 12, Responsible Consumption & Production: green and urban mining (bio-based recycling)

Adriaan Moelker, CEO BRAIN Biotech AG, states: "We take pride to support the UN Global Compact, one of the globally most important initiatives for the corporate sector to adopt sustainable and socially responsible policies. BRAIN develops products and services, which change the way industrial production is done. Our natural and sustainable bio-based processes accelerate the economic transformation to a circular economy. In addition, we incorporate sustainability aspects and good corporate governance in the daily management of our operations. Acting responsibly is elementary for all of BRAIN's stakeholders so that I am personally heading our ESG initiatives. We are currently preparing a corporate sustainability report to document our goals and their implementation also under the framework of the UN Global Compact."
 

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

 

About BRAIN

BRAIN Biotech AG ("BRAIN") is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.

The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.

Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

About UN Global Compact

The United Nations Global Compact is a non-binding United Nations pact to encourage businesses and firms worldwide to adopt sustainable and socially responsible policies, and to report on their implementation. The UN Global Compact is a principle-based framework for businesses, stating ten principles in the areas of human rights, labor, the environment and anti-corruption. Under the Global Compact, companies are brought together with UN agencies, labor groups and civil society. Cities can join the Global Compact through the Cities Programme.

Further details at:
https://www.unglobalcompact.org/what-is-gc

Contact Investor Relations
Michael Schneiders
Head of Investor Relations & Sustainability
Phone: +49 6251 9331-86
Email: mis@brain-biotech.com

Media Contact
Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

 

Follow BRAIN Biotech on Twitter (@BRAINbiotech) and on LinkedIn (@BRAIN AG)



08.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

News im Fokus

Vonovia SE: Vonovia verkauft Berliner Wohnungsbestände aus dem Zukunfts- und Sozialpakt Wohnen

17. September 2021, 12:40

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

CR Capital AG

Original-Research: CR Capital AG (von First Berlin Equity Research GmbH): Buy

17. September 2021